WuXi Biologics signs lease for US clinical-stage facility

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Oleksii Liskonih)
(Image: Getty/Oleksii Liskonih)

Related tags Wuxi biologics Clinical supply New jersey

The CDMO announces the lease of its third site in the US, the latest being focused on clinical supply.

The Chinese contract development and manufacturing organization (CDMO) has signed a 10-year lease deal for a clinical manufacturing facility in New Jersey, US.

WuXi Biologics will outfit the 66,000-square-foot facility with a total capacity of 6,000L, as well as building process development and quality control labs.

The site will create 100 jobs and add to the company’s rapidly developing manufacturing network in the country.

Last month​, the CDMO secured a land deal for its first location in the US, located in Massachusetts, with this facility being both a clinical- and commercial-stage location.

The same month saw WuXi Biologics agree the lease of a 33,00-square-foot process development lab in King of Prussia, Pennsylvania.

This year has seen WuXi Biologics make a concerted effort to expand its physical presence into Western countries, after three deals in the US and the acquisition of its first European drug product facility, in Germany​.

The deal saw WuXi Biologics take on Bayer’s facility and become a back-up manufacturer for the latter company’s products.

Though it is WuXi Biologics first drug product facility, it is current constructing a second facility​, in Ireland, which will become the world’s largest single-use-focused location.

Related topics Bio Developments Facilities

Related news

Show more

Related product

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers